Duocarmycin DM

[1]Patil PC, et al. A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents. Anticancer Agents Med Chem. 2015;15 (5) :616-630.|[2]Koch MF, et al. Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin Analogues. Angew Chem Int Ed Engl. 2015 Nov 9;54 (46) :13550-4.|[3]Chen KC, et al. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013;10 (5) :1773-1782.|[4]Tietze LF, Krewer B, von Hof JM, Frauendorf H, Schuberth I. Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065. Toxins (Basel) . 2009;1 (2) :134-150. |[5]Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg Med Chem. 2008;16 (12) :6312-6318.